As a fully human monoclonal antibody targeting the bone resorption mediator RANKL, denosumab is effective in postmenopausal osteoporosis, male osteoporosis and glucocorticoid-induced osteoporosis (86–88). This evidence concerns the gene TNFSF11 and postmenopausal osteoporosis.